This is a pre print version of the following article:

Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis / Scott, P; Rutjes, A; Bermetz, L; Robert, N; Scott, S; Lourenço, T; Egger, M; Low, N. - In: VACCINE. - ISSN 0264-410X. - 29:52(2011), pp. 9711-9721. [10.1016/j.vaccine.2011.07.042]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

17/07/2024 20:54

Vaccine xxx (2011) xxx-xxx



Contents lists available at ScienceDirect

# Vaccine



journal homepage: www.elsevier.com/locate/vaccine

# Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: A systematic review and meta-analysis

<sup>3</sup> Q1 Pippa Scott<sup>a</sup>, Anne W.S. Rutjes<sup>a,b</sup>, Lilian Bermetz<sup>a</sup>, Nadège Robert<sup>a</sup>, Susana Scott<sup>c</sup>, Tania Lourenço<sup>d</sup>,
 <sup>4</sup> Matthias Egger<sup>a</sup>, Nicola Low<sup>a,\*</sup>

<sup>a</sup> Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland

- 6 <sup>b</sup> Clinical Center for Aging Sciences (Ce.S.I.), University 'G. d'Annunzio' Foundation, Chieti, Italy
- <sup>c</sup> London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom

8 <sup>d</sup> Health Services Research Unit, University of Aberdeen, United Kingdom

### 10 ARTICLE INFO

12 Article history:

11

16

23

24

25

26

27

28

29

30

31

- 13 Received 10 May 2011
- 14 Received in revised form 8 July 2011
- 15 Accepted 11 July 2011
- Available online xxx
- 17 Keywords:
- 18 Pneumococcal conjugate vaccine
- 19 Immunisation schedule
- 20 Systematic review
- 21 Meta-analysis

## ABSTRACT

*Background:* Pneumococcal conjugate vaccines (PCV) were first licensed for use with 3 primary doses in infancy and a booster dose. The evidence for the effects of different schedules was examined in this systematic review and meta-analysis.

*Methods*: We searched 12 databases and trial registers up to March 2010. We selected randomised controlled trials (RCTs), cohort and case–control studies making direct comparisons between PCV schedules with 2 or 3 primary doses, with or without a booster dose. We extracted data on clinical, nasopharyngeal carriage and immunological outcomes and used meta-analysis to combine results where appropriate.

*Results:* Seropositivity levels (antibody concentration  $\geq 0.35 \,\mu$ g/ml) following 3p and 2p PCV schedules were high for most serotypes (5 RCTs). Differences between schedules were generally small and tended to favour 3p schedules, particularly for serotypes 6B and 23F; between-study heterogeneity was high. Seropositivity levels following 3p+1 and 2p+1 schedules were similar but small differences favouring 3p+1 schedules were seen for serotypes 6B and 23F. We did not identify any RCTs reporting clinical outcomes for these comparisons. In 2 RCTs there was weak evidence of a reduction in carriage of *S. pneumoniae* serotypes included in the vaccine when 3p+0 schedules were compared to 2p+0 at 6 months of age.

*Conclusions:* Most data about the relative effects of different PCV schedules relate to immunological outcomes. Both 3p and 2p schedules result in high levels of seropositivity. The clinical relevance of differences in immunological outcomes between schedules is not known. There is an absence of clinical outcome data from RCTs with direct comparisons of any 2p with any 3p PCV schedule.

© 2011 Elsevier Ltd. All rights reserved.

# 1. Introduction

*Streptococcus pneumoniae* is estimated to cause over 500,000 deaths in children under 5 years every year and a further 13 million cases of severe disease, including meningitis, septicaemia, and pneumonia [1]. There are more than 90 identified serotypes of *S. pneumoniae*, but only 10 account for most paediatric infections [2]. The existing 23-valent pneumococcal polysaccharide vaccine (PPV), is not licensed for children under 2 years old and its efficacy against invasive pneumococcal disease (IPD) remains controversial [3,4].

\* Corresponding author at: Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, Bern CH-3012, Switzerland. Tel.: +41 31 631 3092; fax: +41 31 631 3520. *E-mail address:* low@ispm.unibe.ch (N. Low).

0264-410X/\$ - see front matter  $\ensuremath{\mathbb{C}}$  2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.vaccine.2011.07.042

Pneumococcal conjugate vaccines (PCVs) are based on the conjugation of selected capsular polysaccharides to a protein carrier. Unlike PPV, they elicit T-cell dependent antibody responses, which make them immunogenic in infants [5]. The first of these vaccines was licensed in the US in 2000 and contains polysaccharide from 7 serotypes conjugated to a mutant diphtheria protein, CRM197 [6]. Since introduction, this vaccine has reduced the burden of invasive disease in young children in the US and offers indirect protection against disease in adults [7]. The licensure application for this vaccine included 2 randomised controlled trials (RCT) that assessed clinical outcomes. Both used a vaccination schedule of 3 primary doses before 7 months of age and a fourth dose at 12–15 months (schedule abbreviated as 3p+1) [8,9]. Since then, vaccines containing 10 and 13 serotypes have been licensed, based mainly on immunological non-inferiority to the 7-valent vaccine and safety data [10-12].

The majority of high income countries have now implemented a variety of PCV schedules into their childhood vaccination 32

33

34

35

36

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

# **ARTICLE IN PRESS**

P. Scott et al. / Vaccine xxx (2011) xxx-xxx

programmes. The World Health Organization (WHO) recommends a schedule of 3 primary doses without a booster (3p+0) [13] based on the results of RCTs in South Africa and the Gambia [14,15]. However, since PCVs induce immunological memory, it has been suggested that a schedule of 2 primary doses with a third dose in the second year of life (2p+1) might improve the duration of the immune response and ensure a strong herd effect [16]. This schedule has been introduced in several countries including the United Kingdom and France [17].

Schedules with fewer doses would be preferred, particularly in resource poor settings and countries where the routine immunisation schedule does not include a visit in the second year of life. Many middle and low income countries are currently in the process of making decisions about which PCV and which schedule to use and additional research about the use of alternative PCV schedules has been recommended [13]. We systematically reviewed data from studies that compared schedules containing 3 primary doses (with or without a booster) with 2 primary doses (with or without a booster).

## 2. Materials and methods

We followed a study protocol, which was developed with advice from an international expert group (see supplementary online text file 1).

# 2.1. Study identification

We searched 12 databases and trial registries (see supplementary online text) from their earliest date. The searches were conducted on August 28th 2009 and the Embase.com search was repeated on March 17th 2010. We used thesaurus and free text search terms adapted to each database relating to pneumococcus, streptococcus, conjugated vaccine, immunisation, or names of licensed pneumococcal conjugate vaccines. There were no restrictions on language, study design, or date of publication (full details in supplementary online text). Additionally, we screened bibliographies of selected review articles and asked experts in the field and vaccine manufacturers for other studies that might fit our inclusion criteria.

## 2.2. Study selection

Two pairs of reviewers independently evaluated articles. Titles and abstracts were screened first and then full text articles of potentially eligible items were read. We included RCTs, quasi-RCTs, cohort and case-control studies that enrolled children up to 18 years. We included data on licensed 7-, 10- or 13-valent PCVs and on 9-valent PCV, which contains serotypes 1 and 5 in addition to those in the 7-valent vaccine and is also conjugated to CRM197 [2]. Studies were eligible if they directly compared the following PCV schedules: 3p+0 vs. 2p+0; 3p+0 vs. 2p+1; 3p+1 vs. 2p+1; 3p+1 vs. 3p+0. We also studied the effects of a PPV booster in 2 direct comparisons with a PCV booster: 3p+1 vs. 3p+PPV and 2p+1 vs. 2p+PPV (protocol, p4, study questions). Data about antibody concentrations after the administration of PPV are reported in these 2 comparisons only. Studies were not eligible for inclusion if they only compared schedules to a control group that did not receive PCV. Eligible studies reported clinical, nasopharyngeal carriage or immunological outcomes. Observational studies reporting data only from individuals with an outcome (case-only studies) were excluded, as were those where all vaccinated children were HIV-infected, and all unvaccinated children were HIV-uninfected.

### 2.3. Data abstraction

Data were extracted on to a structured piloted form and checked for accuracy and completeness by PS. Data about the following outcomes, using definitions provided by study authors, were extracted: clinical outcomes including IPD, bacteraemia, pneumonia, otitis media, nasopharyngeal *S. pneumoniae* carriage, and immunological outcomes including IgG and opsonophagocytic activity (OPA). We extracted data on the potential risk of bias in individual trials including information on concealment of allocation sequences and blinding of outcome assessors [18]. Authors of individual studies were contacted only if reports of outcome data differed between publications of the same study.

2.4. Analysis

RCTs were analysed separately from observational studies. The primary outcomes of interest were clinical, followed by carriage and immunological outcomes. RCTs with groups that received a booster could contribute to more than one comparison. For example, if antibody concentrations were assessed in both groups after the primary vaccination series, these data were included in comparisons of 3p+0 vs. 2p+0 and of 3p+1 vs. 2p+1. We planned to use data from intention to treat (ITT) analyses but included data from per protocol (PP) analyses when ITT data were not available. For nasopharyngeal carriage outcomes we calculated the ratio (with 95% confidence intervals, CI) of the odds of carriage in children receiving the 3-dose compared with the 2-dose schedule as the reference group [19]. For immunological outcomes we calculated the absolute difference (with 95% CI) between the proportions seropositive following the 3-dose and 2-dose schedules. We considered IgG antibody levels measured by any enzyme-linked immunoassay (ELISA) above a threshold of 0.35 µg/ml as seropositive for all serotypes, as recommend by WHO [20]. An ELISA incorporating a 22F adsorption step has been accepted for use in licensure applications with a threshold of  $0.20 \,\mu\text{g/ml}$  [21]. However, the  $0.35 \,\mu\text{g/ml}$  threshold was the most consistently reported, and the prevalence difference and between trial heterogeneity were consistent regardless of the threshold. We report geometric mean concentration (GMC) data where seropositivity data were not available. We examined the association between OPA and IgG across trials that measured both outcomes. For each trial group we plotted the proportion with OPA titre  $\geq$ 1:8 against the proportion ELISA seropositive  $(\geq 0.35 \,\mu g/ml).$ 

We combined data statistically, where appropriate, using Der-Simonian and Laird random-effects meta-analysis [22] in STATA version 10 (StataCorp LP, College Station, TX, USA). We quantified between-trial heterogeneity using the  $l^2$  statistic; the proportion of the total variation in estimated prevalence ratios due to betweentrial heterogeneity rather than to chance [23].  $l^2$  values of 25%, 50% and 75% can be interpreted as low, moderate and high levels of heterogeneity, respectively.

# 3. Results

Initial database searches yielded 3121 items and another 96 came from reference lists, experts, or repeat database searches, giving a total of 3217 unique items. Of these, 3188 items were excluded (Fig. 1). The remaining 29 items referred to 8 trials, 1 cohort study and 1 case–control study reporting on eligible comparisons and outcomes. Six trials and the cohort study contributed to immunological outcome comparison and 2 trials to nasopharyngeal carriage 109

111

112

113

114

115

122

124

125

126

127

128

129

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

164

165

166

167

168

P. Scott et al. / Vaccine xxx (2011) xxx-xx



Fig. 1. Flow chart of studies. \*175 full text items reviewed for eligibility in both RCT and cohort/case–control reviews as potential randomised and observational components. AIM, African Index Medicus; EMEA, European Medicines Agency; FDA, U.S. Food and Drug Administration; GSK, GlaxoSmithKline; IndMed, Indexing of Indian Medical Journals; LILACs, Latin American and Caribbean Health Sciences; mRCT, metaRegister of Controlled Trials; PCV; RCT, Randomised controlled trial; WHO Portal, World Health Organisation Clinical Trials Search Portal; UKCTG, UK Clinical Trials Gateway.

comparisons. Only the case–control study reported clinical out-comes.

# 171 3.1. Description of included studies

## 172 3.1.1. RCTs

The 8 RCTs were conducted in a total of 10 countries (Table 1). 173 1153 infants were randomised to schedules with 3 primary doses, 174 and 948 to schedules with 2 primary doses. Three RCTs used 7-175 valent PCV (Fiji 7v [24], Gambia 7v [25], Israel 7v [26]), 4 used 176 9-valent PCV (Ghana 9v [27], Iceland 9v [28], UK1 9v [29], UK2 9v 177 [29]) and 1 used 10-valent PCV (Europe 10v [30]). One RCT studied 178 children with sickle-cell disease (Ghana 9v); the rest included chil-179 180 dren from the general population. Table 2 shows methodological features of the 8 RCTs, including adequacy of allocation conceal-181

ment, the use of outcome assessor blinding and the type of analysis (intention to treat or per protocol). Analyses were intention to treat in 1 trial, per protocol in 2 and unclear in the remaining trials. It remained unclear whether the allocation concealment was adequate and whether outcome assessors were blinded for all trials, except Fiji 7v where laboratory staff were blinded.

## 3.1.2. Cohort and case-control studies

One cohort study (UKobs 9v [29]) compared groups from UK1 9v and UK2 9v RCTs which allowed comparisons that were not available from the randomised components of these studies (3p+0 vs. 2p+0; 3p+1 vs. 2p+1). This cohort study reported immunological outcomes only. The case–control study (USAobs 7v [31]) enrolled 782 cases of IPD and 2512 controls. 188

P. Scott et al. / Vaccine xxx (2011) xxx-xxx

# 4

# Table 1

Summary of included RCTs with schedule-schedule comparisons, alphabetical order.

Study name, country and PCV valency [ref] <sup>a</sup>	Schedule	Age at dose in months, mean		No. randomised	Outcomes reported	Time points for analysis, months
		Intended	Actual			
Europe (Denmark, Norway, Slovakia, Sweden) 10v [30]	3p+1	2, 3, 4, +b11m	1st: mean 2.8	176	Seropositivity, GMC, OPA	6, 11, 12
			2nd: mean 3.9			
			3rd: mean 5.0			
			Booster: mean 11.2			
			1st: mean 2.8	175		
			2nd: mean 4.9			
	2p+1	2, 4, +b11m	Booster: mean 11.1			
Fiji 7v [24]	3p+0	1.5, 2.5, 3.5	NR	136	Carriage, Seropositivity, GMC	4.5, 9, 12, 17 <sup>b</sup>
	2p+0	1.5, 3.5		156		
Gambia 7v [25]	3p+PPV	2, 3, 4+10(PPV)	NR	228	Carriage, Seropositivity	5, 11, 15
	2p+PPV	2, 3 + 10(PPV)		228		
Ghana 9v (sickle-cell) [27]	3p+1	1.5, 2.5, 3.5 + 12	2.6, 3.9, 4.8, NR	21	GMC	13
	3p+PPV	1.5, 2.5, 3.5 + 12(PPV)	2.4, 3.5, 4.9, NR	21		
	3p+0	1.5, 2.5, 3.5	2.4, 3.9. 5.2	20		
Iceland 9v [28]	3p+1	3, 4, 5+12	NR	1110	Seropositivity, GMC	6, 12, 13
	3p+PPV	3, 4, 5 + 12(PPV)		111		
	2p+1	3, 5 + 12		1120		
	2p+PPV	3, 5+12(PPV)		112		
Israel 7v [26]	3p+1	2, 4, 6+12	NR	178	Seropositivity, GMC	7, 13, 19
	3p+0	2, 4, 6		178		
	2p+1	4,6+12		189		
UK1 9v [29]	2p+1	2, 4+12	NR	88c	Seropositivity, GMC	13
	2p+PPV	2, 4+12(PPV)		00		
UK2 9v [29]	3p+1 3p+PPV	2, 3, 4 + 12 2, 3, 4 + 12(PPV)	NR	84 <sup>c</sup>	Seropositivity, GMC	11

<sup>a</sup> Full list of references relating to each study given in supplementary online text.

<sup>b</sup> Approximately half of each group randomised to receive PPV at 12 m, 17 m data restricted to those not receiving PPV.

<sup>c</sup> The number undergoing the randomisation process. The number randomised to each group is unclear GMC, geometric mean concentration; NR, not reported; OPA, opsonophagocytic activity; PCV, pneumococcal conjugate vaccine; PPV, pneumococcal polysaccharide vaccine; 3p, 3 dose primary schedule, etc.; +1, booster dose.

# Table 2

Reporting of methodological features of RCTs, alphabetical order.

Study, vaccine (manufac- turer)	Intended interval between doses in primary series	Intended interval from last primary dose to sampling <sup>a</sup>	Adequate randomisation sequence generation	Adequate randomisation allocation concealment	Blinding of outcome assessors	Intention to treat or per protocol analyses
Europe 10v (GSK) [30]	2p: 2 mo 3p: 1 mo	Same in all groups	Unclear, 'randomised'	Unclear, 'randomised'	NR	PP
Fiji 7v (Wyeth) [24]	2p: 2 mo 3p: 1 mo	Same in all groups	Yes	Unclear (opaque envelopes but not clear if envelope linked to child before opening)	Laboratory staff blinded	NR
Gambia 7v (Wyeth) [25]	2p: 1 mo 3p: 1 mo	Differs between groups	Unclear, 'consecutively randomised'	Unclear, 'consecutively randomised'	NR	ITT
Ghana (sickle-cell) 9v (Wyeth) [27]	3p: 1 mo	Same in all groups	Yes	Unclear (envelopes used but not clear if envelope linked to child before opening)	NR	NR
Iceland 9v, (Wyeth) [28]	2p: 2 mo 3p: 1 mo	Same in all groups	Unclear, 'randomised'	Unclear, 'randomised'	NR	PP
Israel 7v, (Wyeth) [26]	2p: 2 mo 3p: 2 mo	Same in all groups	Yes	Unclear (opaque envelopes but not clear if envelope linked to child before opening)	NR	NR
UK1 infants 9v (Wyeth) [29]	2p: 2 mo	Same in all groups	Unclear, 'randomised'	Unclear, 'randomised'	NR	NR
UK2 infants 9v (Wyeth) [29]	3p: 1 mo	Same in all groups	Unclear, 'randomised'	Unclear, 'randomised'	NR	NR

All assessments based on information contained in published articles or pre-publication manuscripts. Authors of individual trials were not contacted for information on methodological features.

<sup>a</sup> Where one group receives booster PCV and another not, the classification of 'same in all groups' indicates that the time between last primary dose and sampling is the same in each group. ITT, intention to treat; NR, not reported; PP, per protocol.

# P. Scott et al. / Vaccine xxx (2011) xxx-xx

Serotype Study		Prevalence diff (95% CI)	n/N (%), 3p+0	n/N (%), 2p+0
Serotype 1 Iceland 9v Europe 10v Subtotal (I-squared = 88.1%, p = 0.004)	+	0.00 (-0.02, 0.02) 0.04 (-0.03, 0.12) 0.02 (-0.09, 0.13)	110/110 (100.0) 137/151 (90.7)	108/108 (100.0) 132/153 (86.3)
Serotype 4 Fiji 7v Gambia 7v Israel 7v Iceland 9v Europe 10v Subtotal (I-squared = 57.5%, p = 0.052)	+ + + + ↓	0.01 (-0.01, 0.04) 0.05 (0.02, 0.08) 0.02 (-0.02, 0.05) 0.00 (-0.02, 0.02) 0.00 (-0.05, 0.05) 0.02 (-0.00, 0.04)	125/125 (100.0) 209/210 (99.5) 297/302 (98.3) 110/110 (100.0) 145/153 (94.8)	144/146 (98.6) 199/211 (94.3) 152/157 (96.8) 108/108 (100.0) 145/153 (94.8)
Serotype 5 Iceland 9v Europe 10v Subtotal (I-squared = 0.0%, p = 0.589)		0.03 (-0.02, 0.08) 0.05 (0.01, 0.08) 0.04 (0.01, 0.07)	107/110 (97.3) 148/149 (99.3)	102/108 (94.4) 144/152 (94.7)
Serotype 6B Fiji 7v Gambia 7v Israel 7v Iceland 9v Europe 10v Subtotal (I-squared = 88.1%, p < 0.001)		0.10 (0.01, 0.19) 0.38 (0.30, 0.46) 0.25 (0.17, 0.34) 0.24 (0.13, 0.36) 0.04 (-0.07, 0.15) 0.21 (0.08, 0.33)	109/125 (87.2) 179/193 (92.7) 261/302 (86.4) 95/110 (86.4) 73/149 (49.0)	113/146 (77.4) 104/191 (54.5) 96/157 (61.1) 67/108 (62.0) 67/149 (45.0)
Serotype 7F Europe 10v		0.07 (0.02, 0.11)	151/152 (99.3)	142/153 (92.8)
Serotype 9V Fiji 7v Gambia 7v Israel 7v Iceland 9v Europe 10v Subtotal (I-squared = 83.1%, p < 0.001)	+ + + +	0.05 (0.01, 0.09) 0.09 (0.03, 0.14) 0.03 (-0.01, 0.08) 0.00 (-0.03, 0.03) 0.10 (0.04, 0.16) 0.05 (0.00, 0.10)	125/125 (100.0) 194/205 (94.6) 291/302 (96.4) 109/110 (99.1) 147/153 (96.1)	139/146 (95.2) 177/206 (85.9) 146/157 (93.0) 107/108 (99.1) 131/152 (86.2)
Serotype 14 Fiji 7v Gambia 7v Israel 7v Iceland 9v Europe 10v Subtotal (I-squared = 76.9%, p = 0.002)		0.09 (0.04, 0.14) 0.11 (0.05, 0.18) 0.05 (-0.00, 0.10) 0.00 (-0.04, 0.04) 0.07 (0.02, 0.12) 0.06 (0.02, 0.11)	124/125 (99.2) 188/204 (92.2) 286/302 (94.7) 108/110 (98.2) 149/152 (98.0)	132/146 (90.4) 169/209 (80.9) 141/157 (89.8) 106/108 (98.1) 138/152 (90.8)
Serotype 18C Fiji 7v Gambia 7v Israel 7v Iceland 9v Europe 10v Subtotal (I-squared = 81.2%, p < 0.001)		0.03 (-0.03, 0.10) 0.13 (0.07, 0.19) 0.05 (0.00, 0.10) -0.01 (-0.05, 0.03) 0.10 (0.04, 0.16) 0.06 (0.00, 0.11)	117/125 (93.6) 199/210 (94.8) 291/302 (96.4) 107/110 (97.3) 149/153 (97.4)	132/146 (90.4) 172/210 (81.9) 143/157 (91.1) 106/108 (98.1) 133/152 (87.5)
Serotype 19F Fiji 7v Gambia 7v Israel 7v Iceland 9v Europe 10v Subtotal (I-squared = 0.0%, p = 0.485)	+ + + + + *	0.01 (-0.02, 0.03) 0.02 (-0.02, 0.07) 0.04 (-0.01, 0.10) 0.03 (-0.02, 0.09) 0.02 (0.00, 0.04)	124/125 (99.2) 194/204 (95.1) 282/302 (93.4) 109/110 (99.1) 144/152 (94.7)	144/146 (98.6) 189/204 (92.6) 140/157 (89.2) 104/108 (96.3) 139/152 (91.4)
Serotype 23F Fiji 7v Gambia 7v Israel 7v Iceland 9v Europe 10v Subtotal (I-squared = 87.8%, p < 0.001)		0.12 (0.05, 0.20) 0.38 (0.30, 0.47) 0.15 (0.07, 0.23) 0.09 (-0.01, 0.18) 0.09 (-0.02, 0.20) 0.17 (0.06, 0.28)	118/125 (94.4) 170/197 (86.3) 257/302 (85.1) 99/110 (90.0) 98/152 (64.5)	120/146 (82.2) 98/205 (47.8) 110/157 (70.1) 88/108 (81.5) 85/153 (55.6)
_ 2 _ 1				
Favours 2 dose schedule	Favours 3 dose sc	hedule		

Difference in proportions seropositive

**Fig. 2.** 3p vs. 2p schedules, ELISA seropositivity at threshold 0.35 μg/ml, about age 6 months, by serotype (random-effects meta-analysis). n/N, number seropositive/total in group; prevalence diff, difference in seropositivity between groups shown as a proportion. Horizontal axis represents the difference, expressed as a proportion between groups schedules of 3 primary doses vs. 2 primary doses. Vertical line through risk difference of 0 shows no difference in levels of seropositivity between groups. Solid black diamonds represent point estimate of prevalence difference; horizontal black line represents 95% confidence interval. Open diamond represents the pooled estimate, combined using random effects meta-analysis; vertical points of diamond represent point estimate and horizontal points represent 95% confidence interval; *l*<sup>2</sup> value is the level of statistical heterogeneity between trials (<25% low heterogeneity).

# 3.2. Comparisons between 3 primary and 2 primary dose schedules

Immunological outcomes were reported most often so these are
 described first, followed by clinical outcomes and nasopharyngeal
 carriage.

# 200 3.2.1. Immunological outcomes

3.2.1.1. 3p+0 vs. 2p+0 schedules. Five RCTs (Fiji 7v, Gambia 7v, Israel
7v, Iceland 9v, Europe 10v) and 1 cohort study (UKobs 9v) reported
on this comparison at approximately 6 months of age. In addition,
2 studies reported data at around 12 months of age (Fiji 7v, Iceland

9v), and 1 study in the second year of life (Fiji 7v). The percentage of children randomised who had blood drawn was high (above 80%) for all studies and time points.

At around 6 months of age, the proportion of children seropositive was generally high in both groups (Fig. 2). Differences varied between studies and serotypes but favoured the 3p+0 groups in almost all cases. The largest differences (as well as marked heterogeneity) were seen for serotypes 6B and 23F. For the serotypes with the least between-trial heterogeneity (5 and 19F) differences were small and confidence intervals did not cross the null. Gambia 7v favoured the 3-dose group more strongly for most serotypes. In this trial, the 3-dose group received PCV 1 month before antibody lev-

5

216

205

206

207

208

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

# ARTICLE IN PRESS

P. Scott et al. / Vaccine xxx (2011) xxx-xxx

Serotype Study		Prevalence diff (95% CI)	n/N (%), 3+1 group	n/N (%), 2+1 group
Serotype 1 Iceland 9v Europe 10v Subtotal (I-squared = 0.0%, p = 0.507)	<b>+</b>	0.00 (-0.04, 0.04) 0.02 (-0.02, 0.06) 0.01 (-0.02, 0.04)	46/46 (100.0) 143/147 (97.3)	45/45 (100.0) 149/156 (95.5)
Serotype 4 Iceland 9v Europe 10v Subtotal (I-squared = 0.0%, p = 0.334)	<b>→</b>	0.02 (-0.04, 0.08) 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01)	46/46 (100.0) 147/147 (100.0)	44/45 (97.8) 155/155 (100.0)
Serotype 5 Iceland 9v Europe 10v Subtotal (I-squared = 0.0%, p = 0.598)		0.02 (-0.04, 0.08) 0.01 (-0.02, 0.03) 0.01 (-0.01, 0.03)	46/46 (100.0) 146/147 (99.3)	44/45 (97.8) 153/155 (98.7)
Serotype 6B Iceland 9v Europe 10v Subtotal (I-squared = 0.0%, p = 0.491)		0.04 (-0.04, 0.13) 0.08 (0.02, 0.14) 0.07 (0.02, 0.12)	45/46 (97.8) 140/147 (95.2)	42/45 (93.3) 136/156 (87.2)
Serotype 7F Europe 10v	+	0.00 (-0.01, 0.01)	147/147 (100.0)	156/156 (100.0)
Serotype 9V Iceland 9v Europe 10v Subtotal (I-squared = 0.0%, p = 0.778)	→ → ◇	0.00 (-0.04, 0.04) 0.01 (-0.01, 0.02) 0.01 (-0.01, 0.02)	46/46 (100.0) 147/147 (100.0)	45/45 (100.0) 155/156 (99.4)
Serotype 14 Iceland 9v Europe 10v Subtotal (I-squared = 34.9%, p = 0.215)	+ ~	0.04 (-0.03, 0.12) -0.00 (-0.03, 0.02) 0.01 (-0.03, 0.05)	46/46 (100.0) 145/147 (98.6)	43/45 (95.6) 154/156 (98.7)
Serotype 18C Iceland 9v Europe 10v Subtotal (I-squared = 63.7%, p = 0.097)	*	0.04 (-0.03, 0.12) -0.01 (-0.03, 0.01) 0.01 (-0.05, 0.07)	46/46 (100.0) 146/147 (99.3)	43/45 (95.6) 156/156 (100.0)
Serotype 19F Iceland 9v Europe 10v Subtotal (I-squared = 41.0%, p = 0.193)		-0.02 (-0.08, 0.04) 0.02 (-0.02, 0.06) 0.01 (-0.04, 0.05)	45/46 (97.8) 144/147 (98.0)	45/45 (100.0) 149/156 (95.5)
Serotype 23F Iceland 9v Europe 10v Subtotal (I-squared = 0.0%, p = 0.620)		0.07 (-0.04, 0.18) 0.04 (-0.02, 0.09) 0.04 (-0.00, 0.09)	44/46 (95.7) 141/147 (95.9)	40/45 (88.9) 142/154 (92.2)
		2 4		
21 Favours 2p+1 schedule	Favours	.o .4 3p+1 schedule		

Difference in proportions seropositive

**Fig. 3.** 3p+1 vs. 2p+1, ELISA threshold 0.35 µg/ml, 1 month after booster dose, age about 12 months (random effects meta-analysis). n/N, number seropositive/total in group; prevalence diff, difference in seropositivity between groups shown as a proportion. Horizontal axis represents the difference, expressed as a proportion between groups receiving schedules of 3 primary and 1 booster dose vs. 2 primary and 1 booster dose. Vertical line through risk difference of 0 shows no difference in levels of seropositivity between groups. Solid black diamonds represent point estimate of prevalence difference; horizontal black line represents 95% confidence interval. Open diamond represents the pooled estimate, combined using random effects meta-analysis; vertical points of diamond represent point estimate and horizontal points represent 95% confidence interval; *l*<sup>2</sup> value is the level of statistical heterogeneity between trials (<25% low heterogeneity).

els were measured whilst the 2-dose group received PCV 2 months before; in all other studies the interval between the last vaccine dose and antibody measurement was the same in both arms. By 12 months of age, the proportions seropositive had dropped by varying degrees for all serotypes except 6B where percentages had dropped slightly in Fiji 7v, and increased slightly in Iceland 9v (data not shown). Percentages seropositive were around 60% or below for serotypes 4 (Iceland 9v), 9V (Iceland 9v), 18C (both studies) and 23F (both studies). By 17 months (Fiji 7v) the proportions seropositive had dropped further for all serotypes except 9V and 19F, which remained >90%. The prevalence differences between schedules were similar to the differences at 6 months of age.

The cohort study (UKobs 9v) compared immunogenicity data following a 3p+0 schedule (2, 3 and 4 months) in one county with a 2p+0 schedule (2 and 4 months) in another, with broadly similar results 1 month after the last primary vaccination [29]. At 12 months of age (8 months after vaccination), there were more marked differences between the groups and overall levels of seropositivity had fallen for most serotypes (33–98% seropositive at a threshold of 0.35  $\mu$ g/ml). 3.2.1.2. 3p+0 vs. 2p+1 schedules. There was 1 RCT (Israel 7v) that compared a 3p+0 (2, 4 and 6 months) with a 2p+1 (4, 6 and 12 months) schedule. Proportions seropositive at a threshold of 0.35 µg/ml were not reported for assessments after the booster dose. At 13 months, GMCs in the 3p+0 group (7 months after the last primary dose) were around one tenth of those in the 2p+1 group (1 month after the booster) for all serotypes. By 19 months of age GMCs were more similar with values in the 3p+0 group (13 months after the last primary dose) around half of those in the 2p+1 group (7 months after the booster) for all serotypes except 4 (GMC in the 3p+0 group around quarter of the 2p+1 group).

3.2.1.3. 3p+1 vs. 2p+1 schedules. Two RCTs reported on a 3p+1 vs. 2p+1 comparison and had seropositivity data at the  $0.35 \mu g/ml$  level (Iceland 9v, Europe 10v) (Fig. 3). One month after a booster dose, the proportions seropositive were >90% for all serotypes except 6B in the Europe 10v study for the 2p+1 group, and 23F for the 2p+1 group in Iceland 9v. There were no data at this cut-off at older ages. In the UKobs 9v study, half the children in the 3p and 2p groups received a booster dose at 12 months. Only GMCs were

on 3 and 2 primary doses: A

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

P. Scott et al. / Vaccine xxx (2011) xxx-xxx

256

257

reported at this time point. One month after the booster dose there was no statistical evidence of differences between groups.

3.2.1.4. 3p+1 vs. 3p+0. The 3p+1 vs. 3p+0 comparison was exam-258 ined by 2 RCTs (Ghana 9v, Israel 7v), neither of which reported 259 the proportions seropositive ( $\geq 0.35 \,\mu g/ml$ ) after the booster dose. 260 GMC ratios between intervention groups showed little heterogene-261 ity between the two studies despite the Ghana children having 262 sickle-cell disease. One month after the booster dose (7 months 263 after the last primary dose in the 3p+0 group) pooled GMC values 264 for all serotypes in 3p+1 groups were 5 to 15 times higher than in 265 the 3p+0 groups. By 19 months of age (7 months after the booster) 266 GMCs were more similar with values in the 3p+1 group around 1.5 267 to 3 times higher than those in the 3p+0 group. 268

3.2.1.5. 2p+1 vs. 2p+PPV and 3p+1 vs. 3p+PPV. One study reported 269 seropositivity (at a cut-off of  $0.35 \,\mu g/ml$ ) data for the 2p+1 vs. 270 2p+PPV and 3p+1 vs. 3p+PPV comparisons (Iceland 9v). Results 271 were almost identical in the PCV booster and PPV booster groups, 272 with more than 85% seropositive in both groups for all serotypes 273 after both 2- and 3-dose schedules. UK1 9v and UK2 9v reported 274 275 only GMCs after the booster dose, with variable results for different serotypes and number of primary doses, when comparing groups 276 which received PCV booster to those receiving PPV. 277

3.2.1.6. Opsonophagocytic antibody (OPA). Three RCTs reported 278 results of OPA (Fiji 7v, Gambia 7v, Europe 10v). In general, the pro-279 portions at the group level with OPA titre  $\geq$  1:8 were very similar to 280 the proportions with ELISA antibody levels  $\geq 0.35 \,\mu g/ml$  at around 281 6 months of age (Fig. 4). For serotypes 6B and 23F, the propor-282 tions seropositive were higher by OPA than ELISA in the Europe 10v 283 trial. Low OPA levels, relative to ELISA, were seen for serotype 14 in 284 Fiji 7v and serotype 19F in Gambia 7v. The percentage of children 285 randomised with results available for OPA analysis varied between 286 studies. OPA data from the Gambia 7v trial appeared to relate to a 287 subset of around 20%. Percentages assessed for OPA in Europe 10v 288 ranged from 55 to 70% by serotype and time point. In Fiji 7v, 85% 289 or more were sampled in each group at 6 months of age. 290

#### 3.2.2. Clinical outcomes 291

There were no clinical outcome data from RCTs with eligible 292 comparisons. In the case-control study of invasive pneumococ-293 cal disease (IPD), adjusted odds ratios (aOR) for disease caused 294 by serotypes included in the vaccine were reported as: 3p+0 vs. 295 2p+0, aOR 1.5 (95%CI 0.54-4.35); 3p+0 vs. 2p+1, aOR 1.5 (95%CI 296 0.15-14.6); 3p+1 vs. 3p+0, aOR 0 (95%CI 0-0.87); 3p+1 vs. 2p+1, aOR 297 0 (95%CI 0–10.1). These comparisons were adjusted for underlying 298 disorders only. 299

### 3.2.3. Nasopharyngeal S. pneumoniae carriage 300

3.2.3.1. 3p+0 vs. 2p+0 schedules. Two trials (Fiji 7v, Gambia 7v) con-301 tributed carriage data (Table 3). Serotypes were grouped as vaccine 302 serotypes (VT) defined as carriage of any of the serotypes in the 303 vaccine, i.e. 4, 6B, 9V, 14, 18C, 19F, 23F (reported in both studies), 304 non-vaccine serotypes (NVT, Fiji 7v only), and carriage of any S. 305 pneumoniae serotype (both studies). At about 6 months of age, the 306 results from both trials were comparable and pooled odds ratios 307 showed no evidence of a difference between 3p+0 and 2p+0 sched-308 ules in the prevalence of carriage of any pneumococcal serotype or 309 of VT. Only one trial reported data beyond 6 months of age for this 310 comparison (Fiji 7v, up to 17 months of age). Confidence intervals 311 crossed 1 for all odds ratios except at 9 months in Fiji for VT. 312

systematic review and meta-analysis. Vaccine (2011), doi:10.1016/j.vaccine.2011.07.042

## 4 Discussion

In this systematic review of immunisation schedules for PCV, immunological data showed that 3p schedules might result in slightly higher antibody levels than 2p schedules both before and after a booster dose, particularly for serotypes 6B and 23F. Results of OPA assessments were generally similar to those of seropositivity assessed by ELISA. There is an absence of clinical outcome data and limited data about nasopharyngeal carriage from direct comparisons of any 2p to any 3p schedule.

# 4.1. Strengths and limitations

This is, to our knowledge, the first systematic review to examine the evidence from direct comparisons of different PCV schedules. Other reviews have focused on the efficacy and/or effectiveness of PCV, comparing outcomes in vaccinated children with those receiving no vaccination or no PCV [33–36]. The strengths of this study include a wide search of databases encompassing published articles, manufacturer and regulatory authority databases and clinical trial registries so relevant RCTs are unlikely to have been missed. If the schedules compared were incompletely reported in abstracts, however, these studies might have been excluded early in the selection process. This is most likely for case-control studies. We also made a comprehensive assessment of potential sources of heterogeneity and bias between trials and compared serotype specific OPA data with ELISA seropositivity. To our knowledge data about OPA have not previously been compared across trials. A limitation identified by this review was the paucity of data on the outcomes and comparisons of interest. Furthermore, we found only 1 eligible study using 10-valent PCV and no studies using the 13-valent PCV were eligible so it is difficult to assess whether these vaccines behave differently to 7-valent vaccine for serotypes common to both vaccines. We explored the possibility of using network meta-analysis to make indirect comparisons whilst respecting the randomisation within trials, but found insufficient data. There is a risk of bias in making informal indirect comparisons between different PCV schedules in placebo (or non-pneumococcal vaccine) controlled trials, such as the large efficacy trials of 3p+0 or 3p+1 in South Africa, the Gambia and the USA.

# 4.2. Interpretation of findings

Please cite this article in press as: Scott P, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: A

The assessment of the merits of different PCV schedules needs to be based on data about immunological and nasopharyngeal carriage outcomes, and data from observational study designs because of an absence of clinical outcome data from RCTs that directly compare different vaccination schedules. There was weak statistical evidence to suggest that the odds of pneumococcal carriage measured 1 month after the last dose were lower following a 3p compared with a 2p schedule; odds ratios are considered the best effect measure for estimating relative frequency of acquisition from cross-sectional data [19]. The evidence was insufficient to draw conclusions on the relative effect of 3p and 2p schedules on the carriage of vaccine type and non-vaccine type S. pneumoniae. Research is currently in progress to assess how carriage data relate to clinical disease [37]. Carriage could potentially be measured directly as the frequency of acquisition of colonisation, where new episodes of carriage are recorded in individuals who have never carried before, or who have carried but cleared the colonisation. These data require frequent collection of samples and are rarely reported.

Immunological data were most often reported but the clinical relevance of differences between schedules in seropositivity levels or GMCs is not known. The threshold IgG level of 0.35 µg/ml for all serotypes has been accepted as a benchmark for protection against IPD 4 weeks after a 3 dose primary series [20,21] but pro-

313

314

315

321 322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

# ARTICLE IN PRESS



**Fig. 4.** Percentage of individuals with OPA > 1:8 compared to percentage of individuals with ELISA > 0.35  $\mu$ g/ml in each randomization group in the three trials reporting these data, about age 6 months, by serotype. Diagonal line represents equal percentages of individuals positive for each outcome. Data in this figure are from the three trials which report both OPA > 1:8 and ELISA > 0.35  $\mu$ g/ml. Each point represents one trial arm from these trials: Fiji 7v 0-, 1-, 2-, 3-dose arms; Gambia 7v 1-, 2-, 3-dose arms; Europe 10v 2-, 3-dose arms. OPA data not available for Fiji 7v for serotype 19F. These data are at the group level and associations at the individual level between the two outcomes may differ to those seen here.

tective levels of antibodies might differ between serotypes [38], 374 for different clinical outcomes [39] and in different populations. 375 The link between seropositivity and IPD was based on analyses of 376 serotypes in the 7-valent vaccine only; there is no known immune 377 correlate of protection against pneumococcal disease for serotypes 378 in extended valency PCVs. It is also not known how immunologi-379 380 cal outcomes relate to carriage. Immunological outcome data need to be interpreted in conjunction with information about pneumo-38 coccal serotype distribution and age-specific incidence of disease. 382 In this review, absolute differences in percentages seropositive 383 following 3p and 2p schedules were mostly <10%. The largest differ-384 ences were observed for serotypes 6B and 23F, which might suggest 385 that a 3-dose primary schedule would be preferred if the burden 386 387 of pneumococcal disease from these serotypes is high in the first year of life. A recent case-cohort study, matched using propen-388 sity scores, in the US found fewer hospitalisations and outpatient 389

attendances for lower respiratory tract disease in the post-primary period in children who received 3 primary doses at median ages of 2.1, 4.2 and 6.2 months compared with 2 doses at median ages 2.2 and 5.7 months [39]. This study was not included in our review because the clinical outcome included conditions not specified in the protocol. Serotypes were not reported, but 6B is the second most common in North America [40] and breakthrough infections have been associated with serotype 6B [38].

Schedules with a booster dose at 12 months (2p+1 or 3p+1) resulted in markedly higher antibody levels than a 3p+0 schedule at 13 months of age (or 1 month after the booster was given) providing a rationale for the use of a schedule with a booster dose when there is a high burden of disease in the second year of life. However, surveillance data from Australia have shown a marked decline in invasive disease since a 3p+0 schedule was implemented in 2005 [41,42]. Comparison of the use of PCV and PPV as the booster

P. Scott et al. / Vaccine xxx (2011) xxx-xxx

# Table 3

406

407

408

409 410

411

Odds ratios for carriage of *S. pneumoniae* at different ages, 3 primary doses *vs.* 2 primary doses.

Serotype, study	Odds ratio (95% CI) <sup>a</sup>						
	About 6 mo	About 9 mo	About 12 mo	About 17 mo			
Any							
Fiji 7v [32]	1.10 (0.69–1.77)	0.73 (0.45-1.18)	0.90 (0.55-1.48)	0.96 (0.48-1.94)			
Gambia 7v [25]	0.77 (0.46-1.29)	NR	NA <sup>b</sup>	NA <sup>b</sup>			
Pooled, <sup>c</sup> <i>I</i> <sup>2</sup>	0.94 (0.66-1.33), 0.0%	NA	NA	NA			
Vaccine type							
Fiji 7v [32]	0.94 (0.43-2.04)	0.30 (0.10-0.92)	1.12 (0.42-3.01)	0.37 (0.04-3.63)			
Gambia 7v [25]	0.69 (0.41-1.17)	NR	NA <sup>b</sup>	NA <sup>b</sup>			
Pooled, <sup>c</sup> I <sup>2</sup>	0.76 (0.50-1.17), 0.0%	NA	NA	NA			
Non-vaccine type							
Fiji 7v [32]	1.20 (0.74-1.96)	0.95 (0.59-1.55)	0.86 (0.52-1.44)	NR			
Gambia 7v [25]	1.02 (0.68-1.55)	NR	NA <sup>b</sup>	NA <sup>b</sup>			
Pooled, <sup>c</sup> <i>I</i> <sup>2</sup>	1.09 (0.80–1.50), 0.0%	NA	NA	NA			

<sup>a</sup> An odds ratio greater than one indicates that the 3-dose group were more likely to carry than the 2-dose group.

<sup>b</sup> Children received PPV vaccination at 11 months of age and therefore no longer included in this schedule comparison.

<sup>c</sup> Random effects meta-analysis; mo, months; NA, not applicable; NR, not reported; *I*<sup>2</sup>, measure of between trial heterogeneity.

dose was a pre-specified question in this review. There were few data available, however, and all were immunological. Interpretation of these data is further complicated by differences in how IgG antibody concentrations generated through PCV or PPV vaccination relate to antibody avidity and underlying immune responses [29,43].

There are several possible reasons for the marked heterogene-412 ity between RCTs in differences between seropositivity following 413 3p and 2p schedules, including differing risk of bias between stud-414 ies, timing of vaccinations and blood samples, differences in study 415 populations and serotype distribution, vaccine valency and com-416 position, or prevalence of carriage prior to vaccination. With only 5 417 RCTs, it was not possible to investigate heterogeneity in a meta-418 regression analysis. One source of heterogeneity resulting from 419 study design would occur if the time between last vaccine dose and 420 antibody measurement differed between groups. In this review, the 421 Gambia 7v RCT had a 2 month interval after the last primary dose in 422 the 2p group and a 1 month interval for the 3p group. The larger dif-423 ferences favouring the 3p schedule for most serotypes in this trial 424 than in the other 4 studies, suggests that these results were more 425 likely to be due to the difference in sampling interval than to differ-426 ences in immunological responses to the 2 schedules. Additionally, 427 heterogeneity between studies might be less marked if a correlate 428 of protection was known for each serotype, rather than using a uni-429 form threshold. The assessment of functional antibody responses 430 measured by OPA levels is being emphasised increasingly [2]. It has 431 been shown that in individuals, OPA titres correlate well with ELISA 432 antibody concentration for vaccine serotypes but not for vaccine-433 434 related serotypes [44]. In this review, the proportions seropositive 435 by ELISA ( $\geq 0.35 \,\mu g/ml$ ) corresponded well to the proportion OPA positive (titre  $\geq$  1:8) for vaccine serotypes. At the study level, these 436 findings support the correlation between ELISA antibody levels and 437 functional antibody. Serotype-specific hyporesponsiveness to vac-438 cination associated with pneumococcal carriage has been observed 439 [45]. If this occurs, it may also account for some heterogeneity 440 between studies, and would need to be taken in to account when 441 making schedule-related decisions. 442

# 443 4.3. Implications for practice and research

There are now almost as many countries using 2p+1 PCV schedules as the licensed 3p+1 schedule [17]. The decisions to use such schedules are likely to have been based on immunogenicity data. For example, in the UK the Joint Committee on Vaccination and Immunisation cited the UK1 9v trial, 'as it has been shown to provide satisfactory primary immunogenicity and prime for memory responses to a booster dose in the second year of life' [46]. Post-marketing surveillance in individual countries has shown reductions in IPD caused by vaccine serotypes using a 2p+1 schedule [47] but the impact on pneumococcal pneumonia is not known. Additional information will be provided by an ongoing systematic review [48] and comparison of disease surveillance data in countries using 3p+1 schedules (e.g. USA, Canada and The Netherlands) to that in countries using reduced-dose schedules (UK, Israel and Mexico) [49]. Interpretation of findings of studies using the same schedule in different countries will need to take into consideration differences in aspects such as the pattern of circulating serotypes, contact patterns, co-morbidity, and co-administration of other vaccines and other potential confounders that can vary between countries.

There is a window of opportunity for new RCTs with clinical outcomes comparing 3p+1 to reduced dose schedules, especially in large countries or regions that are deciding on schedules for introducing extended valency vaccines. Pragmatic trials using randomised stepped-wedge introduction of different schedules in different areas, accompanied by enhanced surveillance for pneumococcal disease could provide valuable information. The sample sizes required would, however, be even larger than those of the original studies for licensure due to smaller expected differences between groups.

Standards of reporting of future RCTs of PCVs need to improve to assist both interpretation of individual trials and future systematic reviews. In the RCTs included in this review, the lack of reporting of methodological details that are essential for assessing the risk of bias was surprising, considering that the CONSORT statement was published well before most of these studies [50]. Although the risk of bias due to inadequate blinding is reduced when outcomes are objective rather than subjective [51], inadequate concealment of allocation remains a potential source of bias. Poor reporting of these aspects is a failing of many of the included studies. There is potential for biases to be introduced when there is marked loss to follow up. In the data reported here, high percentages of children randomised were available for analysis. However, there were exceptions, particularly for OPA data.

# 5. Conclusion

The introduction of PCV into routine childhood vaccination programmes in high income countries has reduced the incidence of IPD across all age groups. However, the progress of introducing PCV into several low income countries remains slow. The varying country specific burden of diseases as well as varying health infrastructures and resources add to the complexities in the decision making process in determining optimal vaccination programmes. 45

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

G Model JVAC 12067 1–11 10

# **ARTICLE IN PRESS**

P. Scott et al. / Vaccine xxx (2011) xxx-xxx

Thus, information on the benefits on different vaccine schedules is 496 essential if informed decisions are to be made. In this comprehen-497 sive systematic review, we highlight the paucity of data comparing 498 3 doses versus 2 doses of PCV before 1 year of age with or with-499 out a booster dose. Immunological data showed that both 3p and 500 2p schedules result in high levels of seropositivity. 3p schedules 501 might result in slightly higher antibody levels than 2p schedules 502 both before and after a booster dose particularly for serotypes 6B 503 and 23F but the clinical relevance of these differences is not known. 504

# Contributors

505

510

511

512

513

514

515

516

517

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

PS and NL designed the study, PS, AR, LB, NR, SS and TL extracted
 data, PS and TL analysed data, PS, AR, LB, NR, SS, TL, ME and NL
 interpreted data, drafted or revised the article. All authors approved
 the final version.

# Funding

This project received funding from the World Health Organization.

# Disclaimer

The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of the World Health Organization.

# Acknowledgements

We thank the members of the WHO ad hoc working group on
PCV for their contributions to the development of the protocol and
interpretation of the results: Dr. Steve Black, Prof. Ron Dagan, Prof.
Paul Fine, Mr. Nigel Gay, Prof. David Goldblatt, Prof. Keith Klugman, Dr. Shabir Madhi, Dr. Alessia Melegaro, Prof. Kim Mulholland,
Dr. Judith Müller, Dr. Cynthia Whitney. We also thank Dr. Shelagh
Redmond for her help with the preparation of the review.

# Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.vaccine.2011.07.042.

# References

- [1] O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. Lancet 2009;374(9693):893–902.
- [2] Reingold A, Cutts F, Kamau T, Levine O, O'Brien K, Ignacio Santos Preciado J, et al. Detailed review paper on pneumococcal conjugate vaccine. In: Presented to the WHO Strategic Advisory Group of Experts (SAGE) on immunization. 2006. Available from: http://www.who.int/immunization/SAGE\_wg\_detailedreview\_ pneumoVaccine.pdf [cited April 5, 2011].
- [3] Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180(1):48–58.
- [4] Andrews R, Moberley SA. The controversy over the efficacy of pneumococcal vaccine. CMAJ 2009;180(1):18–9.
- [5] Käyhty H, Nurkka A, Soininen A, Väkeväinen M. Immunological basis for immunization series. Module 12: pneumococcal vaccines. World Health Organization; 2009.
- [6] Food and Drug Administration (USA). Pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein). Product approval information. Available from: http://www.fda.gov/cber/products/prevnar.htm [cited April 29, 2009].
   [7] Whitney CC. Earlier Methods and the information of the inform
- [7] Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348(18):1737-46.
   [8] European Medicines Agency (EMEA). Provided the second s
- [8] European Medicines Agency (EMEA). Prevenar. Available from: http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000323/human.med.000987.jsp&murl=menus/medicines/medicines.jsp &mid=WC0b01ac058001d125 [cited November 2010].

- [9] U.S. Food and Drug Administration (FDA). Prevnar. Available from: http://www. fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094057.htm [cited May 20, 2011].
   [10] Furgeary Medicines Access (FNGE) (19)
- [10] European Medicines Agency (EMEA). Assessment report for Synflorix. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000973/human.med.001071.jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d125 [cited December 14, 2009].
- [11] European Medicines Agency (EMEA). Prevenar 13; 2010.
- FDA. Clinical Review of Biologics License Application for Prevnar 13 (Pneumococcal 13valent Conjugate Vaccine (Diphtheria CRM197 Protein)), section 9.3 Clinical Study Protocol # 6096A1-3011 in NCT00761631; 2009.
   Pneumococcal conjugate variable of the transformation of the section of the secti
- [13] Pneumococcal conjugate vaccine for childhood immunization—WHO position paper. Wkly Epidemiol Rec 2007;82(12):93–104.
   [14] Cutts FT Zamas SMA Frances of Construction
- [14] Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebocontrolled trial. Lancet 2005;365(9465):1139–46.
- [15] Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349(14):1341–8.
   [16] Tottar CL Malaguer A. Sandara and Sandara
- [16] Trotter CL, McVernon J, Ramsay ME, Whitney CG, Mulholland EK, Goldblatt D, et al. Optimising the use of conjugate vaccines to prevent disease caused by *Haemophilus influenzae* type b: *Neisseria meningitidis* and *Streptococcus pneumoniae*. Vaccine 2008;26(35):4434–45.
- [17] World Health Organization. WHO vaccine preventable diseases monitoring system: immunization schedules by antigen. Available from: http://apps. who.int/immunization\_monitoring/en/globalsummary/scheduleselect.cfm [November 22, 2010].
- [18] Juni P, Altman DG, Egger M. Systematic reviews in health care-assessing the quality of controlled clinical trials. Br Med J 2001;323(7303):42-6.
   [10] Piete Velde, H. Deven, P. C.
- [19] Rinta-Kokko H, Dagan R, Givon-Lavi N, Auranen K. Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine 2009;27(29): 3831-7.
   [10] Weidel W, Wild C, Standard M, S
- [20] World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. In: Proposed replacement of TRS 927, Annex 2, 2009.
- [21] Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003;21:3265–72.
- [22] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–88.
- [23] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539–58.
- [24] Russell FM, Balloch A, Tang ML, Carapetis JR, Licciardi P, Nelson J, et al. Immunogenicity following one: two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine 2009;27(41):5685–91.
- [25] Ota MO, Akinsola A, Townend J, Antonio M, Enwere G, Nsekpong D, et al. The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine 2011;29(16):2999–3007.
- [26] Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine A randomized controlled trial. Pediatr Infect Dis J 2010;29:756–62.
- [27] Goldblatt D, Akoto O, Ashton L, Asafo-Adje E, Brainsby K, Twumasi P, et al. Immunogenicity and the generation of immune memory following 9-valent conjugate vaccination in Ghanaien infants with sickle cell disease. In: Abstract no. 688, in 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2000.
- [28] Sigurdardottir ST, Davidsdottir K, Arasonc VA, Jonsdottir O, Laudate F, Gruberf WC, et al. Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine 2008;26:4178-86.
   [20] Geldhatt D, Sutthere I, Althou P, Marchang A, Safety A, Safe
- [29] Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006;25(4):312–9.
- [30] Silfverdal SA, Hogh B, Bergsaker MR, Skerlikova H, Lommel P, Borys D, et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J 2009;28:e276–82.
- [31] Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368(9546):1495-502.
- [32] Russell FM, Carapetis JR, Satzke C, Tikoduadua L, Waqatakirewa L, Chandra R, et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol 2010;17(12): 1970–6.
- [33] Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998–2006). Vaccine 2007;25(12):2194–212.
- [34] Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009;(4):CD004977.

645

646

647

648

649

650

651

652

653

654

655

656

657

658 659

660

661

662

663

664

665

666

# ARTICLE IN PRESS

P. Scott et al. / Vaccine xxx (2011) xxx-xxx

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

- [35] Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009;123(6):e1103–10.
   [36] York Health Economics Consortium. Overview of evidence on pneumococcal
  - [36] York Health Economics Consortium. Overview of evidence on pneumococcal vaccines and serotype prevalence (unpublished); 2010.
  - [37] PneumoCarr. *Streptococcus pneumoniae* carriage. Available from: http://www.ktl.fi/roko/pneumocarr/index.html [cited March 24, 2011].
  - [38] Goldblatt D, Southern J, Ashton L, Andrews N, Woodgate S, Burbidge P, et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr Infect Dis J 2010;29(5):401–5.
  - [39] Pelton SI, Weycker D, Klein JO, Strutton D, Ciuryla V, Oster G. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010;28(6):1575–82.
  - [40] Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010;7(10).
  - [41] Williams SR, Mernagh PJ, Lee MH, Tan JT. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust 2011;194(3):116–20.
  - [42] Lehmann D, Willis J, Moore HC, Giele C, Murphy D, Keil AD, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010;50(11):1477–86.
  - [43] Anttila M, Eskola J, Ahman H, Kayhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999;17(15–16):1970–7.

- [44] Nahm MH, Olander JV, Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for *Streptococcus pneumoniae*. J Infect Dis 1997;176(3):698–703.
- [45] Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of *Streptococcus pneumoniae* shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010;201(10):1570–9.
- [46] Joint Committee on Vaccination and Immunisation. Proposed changes to the routine childhood immunisation schedule; 2005. Available from: http://www.dh.gov.uk/prod.consum.dh/groups/dh.digitalassets/@dh/@ab/ documents/digitalasset/dh\_095088.pdf [November 2010].
- [47] Health Protection Agency. Pneumococcal disease. Epidemiological data. Available from: http://www.hpa.org.uk/Topics/InfectiousDiseases/ InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal [cited April 4, 2011].
- [48] Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 2010;85(43): 434–6.
- [49] Meeting of the strategic advisory group of experts on immunization, November 2010--summary, conclusions and recommendations. Wkly Epidemiol Rec 2011;86(1-2):1-16.
- [50] Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134(8):663–94.
- [51] Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008.